Cardiovascular disease (CVD) and the associated rhythm abnormalities manifesting as tachyarrhythmias such as Atrial fibrillation (AF) continue as leading causes of morbidity and mortality in the United States and developed countries 1 . In spite of the exciting momentum of new discoveries which have greatly improved our understanding of several key molecular mechanisms underlying AF, identifying and managing AF during its early onset stage is extremely challenging 2 . Traditionally, direct causes for CVD have been attributed primarily to genes, ischemic heart disease, poor dietary choices and lack of exercise; studies later revealed that diseases such as high blood pressure, diabetes, obesity and chronic kidney disease (CKD) are powerful risk factors that can equally impact the heart and cause pathological structural remodeling, contractile dysfunction, hypertrophy and heart failure (HF) which are well established substrates for AF 3 .
Of these, CKD has emerged as one of the most potent risk factors for developing CVD and particularly AF. In fact, the high rates of mortality reported in CKD patients are mainly due to cardiovascular complications including uremic cardiomyopathy and/or vascular calcifications leading to cardiac complications 4 . Although the reciprocal cross-talk between dysfunctions of kidney and heart is well-known, very few common mechanisms have been conclusively identified that could be targeted to impact both CKD as well as CVD. . Its expression is positively linked to CKD, wherein FGF23 levels increase during the early stages of CKD and believed to play a role in increasing urinary phosphate excretion.
Elevated FGF23 levels are also associated with progression of kidney disease and end stage renal emodeling, contractile dysfunction, hypertrophy and heart failure (HF) which a are r re w w wel el ll l l established substrates for AF 3 .
Of Of Of t t the he hese, , C CK CKD has emerged as one of th he e e m m most potent risk k k fac cto to ors rs rs for developing CVD The most convincing data linking FGF23 to ventricular hypertrophy comes from mouse models of CKD which have shown a direct role for FGF23 in causing cardiac hypertrophy 10 .
Although several mechanisms can be assigned to induce cardiac hypertrophy, altered calcium (Ca
2+
) cycling within the cardiomyocyte has been well documented to play a causal role in triggered arrhythmias (especially AF) as well as cardiac hypertrophy and HF 11 . Interestingly, a causes of worsening prognosis for AF patients 2, 9 . Mathew et al's study also show w ws a a a s st tro ro rong ng ng association between higher FGF-23 and NT pro-BNP, a sensitive marker for myocardial wall e ens ns sio io ion n n an an nd d d he he h mo mo od dy dynamic stress which are in tur ur urn n n a a associated wit th h h inci ci ide de dent n AF 8 . However, the details of this complicated interplay within and between multi-organs spanning the bone-mineral-kidney-heart axis is far from clear; especially, the source and direction of dysfunction in a complicated disease setting such as mineral imbalance and its broad range effects is quite challenging to decipher. Despite all the existing data, the fundamental question as to whether FGF23 directly causes any of the implicated disorders including kidney malfunction, bone-mineral imbalances, CVD and AF or is a beneficial compensatory response that is secondarily recruited to play catalytic roles in other pathways (e.g. Vitamin D metabolism) known to directly affect cardiac structure and function is yet to be determined. Mathew et al 8 have quite clearly delineated a strong association between rising FGF23 levels and incident AF, n patients with elevated FGF23 levels can circumvent the deleterious effects of f h hi high gh g F F FGF GF GF23 23 23 14 14 14 and decrease the incidence of AF.
Th Th The e e cu u urr ren en ent t t study by Mathew et al 8 and p p pre r r v v viously availa abl bl b e da da ata ta ta, , both from basic and cl lin n nic ical studies es, co co conc clu lu lusi si ive ve ely ly ly sh s show ow w t t tha ha at F FGF F2 F23 3 pl lay ay ys a a a r ro role le in n n b bo o oth h h CK CK KD D an an nd d d CV CVD D D vi vi via a a a r re ren na nal l-lmi mi ine ne n ra ra ral l me me eta ta tab bo bol li ism m m a ax xis s s th that at t cou ou ould ld ld p pla la ay y an an an i imp mp mpor or rta a an nt p p par ar art t t i in in e e eit it i h he her r r ca ca c u u usi in ing g or or o w w wor or ors se seni i ing ng g A AF F F.
However, the he d d det et e ai ai ails ls ls o o of f f th t is is is c c com om mpl pl p ic ic cat a ed ed ed i i int nt nter er erp p pla la l y y y wi wi with thin in in a a and nd nd b b bet et etwe we een en en m m mu u ult lt lti-i-or or orga ga gans ns ns s s spa p p nning th h he thereby emphasizing its importance as a potential pathway that could be utilized as a novel risk factor for AF. Future investigations should focus on understanding the fundamental role it plays in the heart in order to identify its true contribution to AF development.
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